FindTrial
Sign In

A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations

Comparison of Clinical Cure Rate of Doxycycline and Levofloxacin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06915688
Acronym
DOLE-COPD
Enrollment
188
Registered
2025-04-08
Start date
2025-04-15
Completion date
2025-07-31
Last updated
2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

COPD

Brief summary

This study will include patients with chronic obstructive pulmonary disease (COPD) who present with an acute exacerbation. Participants will be randomly assigned to receive either doxycycline or levofloxacin for 5 days. The aim is to compare how effective each antibiotic is in improving symptoms after 2 days of treatment.

Detailed description

This randomized controlled trial will evaluate the effectiveness of two antibiotics-doxycycline (a tetracycline) and levofloxacin (a fluoroquinolone)-in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Participants will be assigned to one of the two treatment groups and will receive either doxycycline 100 mg twice daily or levofloxacin 500 mg once daily for 5 days. The primary outcome is clinical cure. This will be evaluated 2 days after completion of antibiotic therapy, based on symptom resolution and laboratory markers.

Interventions

DRUGDoxycycline

Doxycycline will be given to COPD group 1

DRUGLevofloxacin

Levofloxacin given to copd patients

Sponsors

Amina Aslam
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* diagnosed cases of COPD Exacerbation of COPD Able to provide Written consent No anti biotic taken with in past 4 weeks

Exclusion criteria

* hypersensitivity to any drugs Pneumonia evidence on xray/ hrct chest Any other pulmonary condition e.g asthma Pregnancy/breast feeding Taking treatment for other active infections

Design outcomes

Primary

MeasureTime frameDescription
Clinical Cure Rate7 days1. A decrease in the respiratory rate by 20% from the baseline measurement. 2. Restoration of Oxygen saturation levels to within the range of 88-92% on room air. 3. CRP\<10ng/ml 4. decrease in sputum quantity 5. reduction in body temperature below 99•F 6. TLC \<11,000

Countries

Pakistan

Contacts

Primary ContactAmina Aslam, MBBS
mubashirm384@gmail.com+923024748021

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026